The main objective of this work is to provide a topical formulation of a novel thiocolchicoside derivative drug to treat gout inflammation. The drug has been tested in cell-based assays and showed promising effects but it has not yet been formulated for clinical applications, hence there is a great need to find a delivery method that maximizes the therapeutic effect and minimizes detrimental side effects. The latter aspect is of importance due to general toxicity of the compound in question. Gout is one of the most common and painful inflammatory diseases that can affect human beings. In the last two decades, the incidence of gout among adults (age ≥ 18 years) doubled.